Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes During Azacitidine and Lenalidomide Therapy

Background and Rationale. Azacitidine (AZA) is a standard first-line therapy in high-risk MDS. Also its combination with Lenalidomide (LEN) has been tested, but its molecular effect is still under investigation. Here we analyzed the effect of AZA+LEN therapy on gene mutations and microRNA expression in MDS patients.